Κένυα - Αγγλικά - Pharmacy and Poisons Board

zydus healthcare limited ackruti star, unit no. 103, midc, andheri (e), - ceftriaxone for injection u.s.p. - powder for injection - ceftriaxone for injection 250mg - beta-lactamantibacterials: third-generation

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains clonidine hydrochloride 25 ug

Ισραήλ - Αγγλικά - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

Ισραήλ - Αγγλικά - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

Ισραήλ - Αγγλικά - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 4 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.